Search

everythinglearnresearchcommunity

for

Search:↓

A user experienced accelerated hairline recession after adding dutasteride to their regimen of topical finasteride and minoxidil, despite reduced hair shedding. They were informed that ELISA testing for DHT levels can be highly inaccurate.

The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The user discussed their positive experience with Him's Minoxidil and Finasteride product and Biotin pills for hair loss treatment over a year. Another user asked when they started noticing hair thickening and volume increase on their temples.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

The conversation is about whether the Ordinary's Multi-Peptide Serum for hair density can be mixed with finasteride. A video was mentioned that shows the serum being mixed with Stemoxydine.

The user switched from Hims topical finasteride and minoxidil to Musely Hair Pill Bloom+, which includes minoxidil, dutasteride, and other vitamins, and noticed new hair growth but also experienced lower blood pressure. Another user ordered a minoxidil-only pill.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

JeremySoCa's DHT level was 29 ng/dl, considered low, and Estradiol was 26.1 pg/dl within the normal range. They are using topical finasteride for hair loss and had a thyroidectomy due to Graves' disease.

Bicalutamide and spironolactone are being compared for their effectiveness and safety in treating female pattern hair loss. The conversation seeks advice on which is better to use.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

Minoxidil 0.5% MMP® showed better results in parietal-vertex regions for less advanced female pattern hair loss compared to Minoxidil 5%. MMP® with Minoxidil can improve the quality of life for these patients.

The user has been using oral finasteride for over a year and recently added GHK-CU for two months, seeing progress but seeking further improvement, especially on the hairline. They discuss sourcing GHK-CU, its effects, and the importance of third-party testing, while considering additional treatments like dutasteride and hair transplants for better results.

The user is considering using "Grow Gorgeous Intense Hair Density Serum" alongside Minoxidil and is currently taking Finasteride. Some users doubt the serum's effectiveness, while others suggest it may help with hair strength and thickness, but opinions are mixed.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

A user has been taking finasteride for 5 months with no improvement in diffuse hair loss and suspects high levels of prolactin, cortisol, progesterone, and DHEAS, as well as iron, might be contributing to the issue. They are also taking vitamin D to address a deficiency.

Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

The conversation discusses using a combination of redensyl, capixyl, and procapil (RCP) for hair loss, with some users also mentioning minoxidil and finasteride. Users shared mixed experiences, with some suggesting "RevivHair Max Hair Stimulating Serum" for better results, while others reported no noticeable effects from using products like The Ordinary Multi-Peptide Serum.

User asks about Eucapil (fluridil) for hair loss, its effectiveness, safety, and where to buy in Australia. Others share experiences and purchase options.

The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.

GHK-Cu and AHK-Cu peptides show limited success for hair loss, with skepticism about their effectiveness and concerns about misleading claims. Users report better results when combined with treatments like finasteride, dutasteride, minoxidil, and other methods.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

The conversation is about using GHK-Cu, a copper peptide, for hair loss treatment. Users discuss their experiences, dosages, and additional benefits like improved skin and energy.

The user experienced new hair growth after using HIMS topical spray containing finasteride and minoxidil for almost two months, along with weekly dermarolling. Other users confirmed the growth and advised continuing the treatment.